Targeting the methionine cycle for melanoma therapy with 3-O-(3,4,5-trimethoxybenzoyl)-(-)-epicatechin

International Journal of Cancer

Volumn 123, Issue 10, 2008, Pages 2446-2455

  Sánchez del Campo, Luís ^a   Rodríguez López, José Neptuno ^a  

^a UNIVERSITY OF MURCIA   (Spain)

Author keywords

3 O (3,4,5 trimethoxybenzoyl) ( ) epicatechin; DNA methylation; Glutathione; Melanoma therapy; Methionine

Indexed keywords

3 O (3,4,5 TRIMETHOXYBENZOYL)EPICATECHIN; ADENOSINE; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; EPICATECHIN; EPICATECHIN 3 GALLATE; GALLIC ACID DERIVATIVE; GLUTATHIONE; METHIONINE; METHOTREXATE; PROTEIN BAX; PROTEIN BCL 2; S ADENOSYLMETHIONINE; UNCLASSIFIED DRUG; 3-O-(3,4,5-TRIMETHOXYBENZOYL)EPICATECHIN; ANTINEOPLASTIC AGENT; CASPASE 3; CATECHIN; DRUG DERIVATIVE; PRIMER DNA; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; GENE EXPRESSION; GLUTATHIONE METABOLISM; HUMAN; HUMAN CELL; MELANOCYTE; MELANOMA; MELANOMA CELL; METHYLATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN METHYLATION; PROTEIN SYNTHESIS; UPREGULATION; ANIMAL; BIOSYNTHESIS; CONFOCAL MICROSCOPY; DRUG EFFECT; ELECTRON MICROSCOPY; GENE EXPRESSION REGULATION; METABOLISM; NUCLEOTIDE SEQUENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ADENOSINE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BASE SEQUENCE; BLOTTING, WESTERN; CASPASE 3; CATECHIN; CELL LINE, TUMOR; DNA PRIMERS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTATHIONE; HUMANS; MELANOMA; METHIONINE; METHYLATION; MICE; MICROSCOPY, CONFOCAL; MICROSCOPY, ELECTRON; REACTIVE OXYGEN SPECIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 53449102406     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23813     Document Type: Article

References (33)

1. Cellarier E, Durando X, Vasson MP, Farges MC, Demiden A, Maurizis JC, Madelmont JC, Chollet P. Methionine dependency and cancer treatment. Cancer Treat Rev 2003;29:489-99.
2. Anderson ME. Glutathione: an overview of biosynthesis and modulation. Chem Biol Interact 1998;111-112:1-14.
3. Thomas T, Thomas TJ. Polyamines in cell growth and cell death: molecular mechanisms and therapeutic applications. Cell Mol Life Sci 2001;58:244-58.
4. Chudnovsky Y, Khavari PA, Adams AE. Melanoma genetics and the development of rational therapeutics. J Clin Invest 2005;115:813-24.
5. Houghon AN, Polsky D. Focus on melanoma. Cancer Cell 2002; 2:275-8.
6. Koon H, Atkins M. Autoimmunity and immunotherapy for cancer. N Engl J Med 2006;354:758-60.
7. Kufe DW, Wick MM, Abelson HT. Natural resistance to methotrexate in human melanomas. J. Invest Dermatol 1980;75:357-9.
8. Gaukroger J, Wilson L, Stewart M, Farid Y, Habeshaw T, Harding N, Mackie R. Paradoxical response of malignant melanoma to methotrexate in vivo and in vitro. Br J Cancer 1983;47:671-9.
9. Zhao R, Goldman ID. Resistance to antifolates. Oncogene 2003;22:7431-57.
10. Nihal M, Ahmad N, Mukhtar H, Wood GS. Anti-proliferative and proapoptotic effects of (-)-epigallocatechin-3-gallate on human melanoma: possible implications for the chemoprevention of melanoma. Int J Cancer 2005;114:513-21.
11. Navarro-Perán E, Cabezas-Herrera J, García-Cánovas F, Durrant MC, Thorneley RNF, Rodríguez-López JN. The antifolate activity of tea catechins. Cancer Res 2005;65:2059-64.
12. Navarro-Peran E, Cabezas-Herrera J, Sánchez-del-Campo LS, Rodríguez-López JN. Effects of folate cycle disruption by the green tea polyphenol epigallocatechin-3-gallate. Int J Biochem Cell Biol 2007;39:2215-25.
13. Sánchez-del-Campo L, Otón F, Tárraga A, Cabezas-Herrera J, Chazarra S, Rodríguez-López JN. Synthesis and biological activity of a 3,4,5-trimethoxybenzoyl ester analogue of epicatechin-3-gallate. J Med Chem 2008;51:2018-26.
14. Potterf SB, Muller J, Bernardini I, Tietze F, Kobayashi T, Hearing VJ, Gahl WA. Characterization of a melanosomal transport system in murine melanocytes mediating entry of the melanogenic substrate tyrosine. J Biol Chem 1996;271:4002-8.
15. Choi S, Singh SV. Bax and Bak are required for apoptosis induction by sulforaphane, a cruciferous vegetable-derived cancer chemopreventive agent. Cancer Res 2005;65:2035-43.
16. Mato JM, Alvarez L, Ortiz P, Pajares MA. S-adenosylmethionine synthesis: molecular mechanisms and clinical implications. Pharmacol Ther 1997;73:265-80.
17. Garcia-Trevijano ER, Latasa MU, Carretero MV, Berasain C, Mato JM, Avila MA. S-adenosylmethionine regulates MAT1A and MAT2A gene expression in cultured rat hepatocytes: a new role for S-adenosylmethionine in the maintenance of the differentiated status of the liver. FASEB J 2000;14:2511-18.
18. Cai J, Sun WM, Hwang JJ, Stain SC, Lu SC. Changes in S-adenosylmethionine synthetase in human liver cancer: molecular characterization and significance. Hepatology 1996;24:1090-7.
19. Cai J, Mao Z, Hwang JJ, Lu SC. Differential expression of methionine adenosyltransferase genes influences the rate of growth of human hepatocellular carcinoma cells. Cancer Res 1998;58:1444-50.
20. Smit N, Tilgmann C, Karhunen T, Slingerland R, Ulmanen I, Westerhof W, Pavel S. O-methylation of L-dopa in melanin metabolism and the presence of catechol-O-methyltransferase in melanocytes. Pigment Cell Res 1994;7:403-8.
21. Tenhunen J, Heikkila P, Alanko A, Heinonen E, Akkila J, Ulmanen I. Soluble and membrane-bound catechol-O-methyltransferase in normal and malignant mammary gland. Cancer Lett 1999;144:75-84.
22. Sasaki M, Kaneuchi M, Sakuragi N, Dahiya R. Multiple promoters of catechol-O-methyltransferase gene are selectively inactivated by CpG hypermethylation in endometrial cancer. Cancer Res 2003;63:3101-6.
23. Mannisto PT, Kaakkola S. Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev 1999;51:593-628.
24. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet 1999;21:163-7.
25. Widschwendter M, Jones PA. DNA methylation and breast carcinogenesis. Oncogene 2002;21:5462-82.
26. Bestor TH. The DNA methyltransferases of mammals. Hum Mol Genet 2000;9:2395-402.
27. Meyskens FL, Jr, Farmer PJ, Anton-Culver H. Etiologic pathogenesis of melanoma: a unifying hypothesis for the missing attributable risk. Clin Cancer Res 2004;10:2581-3.
28. Picardo M, Maresca V, Eibenschutz L, De Bernardo C, Rinaldi R, Grammatico P. Correlation between antioxidants and phototypes in melanocytes cultures. A possible link of physiologic and pathology relevance. J Invest Dermatol 1999;113:424-5.
29. Obrador E, Carretero J, Ortega A, Medina I, Rodilla V, Pellicer JA, Estrela JM. g-Glutamyl transpeptidase overexpression increases metastatic growth of B16 melanoma cells in the mouse liver. Hepatology 2002;35:74-81.
30. Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, Opitz-Araya X, McCombie R, Herman JG, Gerald WL, Lazebnik YA, Cordón-Cardó C, Lowe SW. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001;409:207-11.
31. Zanon M, Piris A, Bersani I, Vegetti C, Molla A, Scarito A, Anichini A. Apoptosis protease activator protein-1 expression is dispensable for response of human melanoma cells to distinct proapoptotic agents. Cancer Res 2004;64:7386-94.
32. Sullivan DM, Hoffman JL. Fractionation and kinetic properties of rat liver and kidney methionine adenosyltransferase isozymes. Biochemistry 1983;22:1636-41.
33. Tabrizchi R, Bedi S. Pharmacology of adenosine receptors in the vasculature. Pharmacol Ther 2001;91:133-47.